(NASDAQ: DYAI) Dyadic International's forecast annual revenue growth rate of 117.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Dyadic International's revenue in 2026 is $3,807,729.On average, 5 Wall Street analysts forecast DYAI's revenue for 2026 to be $252,010,070, with the lowest DYAI revenue forecast at $182,120,638, and the highest DYAI revenue forecast at $325,215,424. On average, 5 Wall Street analysts forecast DYAI's revenue for 2027 to be $491,849,613, with the lowest DYAI revenue forecast at $249,969,503, and the highest DYAI revenue forecast at $734,604,252.
In 2028, DYAI is forecast to generate $1,665,030,095 in revenue, with the lowest revenue forecast at $1,599,731,939 and the highest revenue forecast at $1,714,003,712.